Answers are grounded in this paper and cite their sources.
Pulmonary hypertension (PH) is a progressive disorder characterized by a substantial symptom burden that adversely affects daily functioning and health-related quality of life. Standardized assessment of symptom severity may support clinical follow-up and symptom-focused care. The Pulmonary Arterial Hypertension Symptom Scale (PAHSS) was developed to assess symptom severity in patients with pulmonary arterial hypertension (PAH); however, a Turkish version has not been psychometrically evaluated. To evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the PAHSS in outpatients with PH, most of whom had PAH. This methodological study was conducted in 130 adult patients followed in a pulmonary hypertension outpatient clinic of a university hospital between March and May 2020. The PAHSS was translated using forward and backward translation procedures and evaluated for content validity by expert review. Construct validity was assessed using exploratory factor analysis (EFA) and confirmatory factor analysis (CFA), in which one-factor, original three-factor, and two-factor models were compared, and by examining associations with clinical indicators. Internal consistency was examined with Cronbach’s alpha, McDonald’s omega, and item-total correlations. Test-retest reliability was evaluated in a subsample of 30 patients using intraclass correlation coefficients (ICC). The mean age of the participants was 60.82 ± 15.40 years, and 78.5% were classified as PH group 1 (PAH). The content validity index was 0.94. EFA suggested a two-factor structure, labelled cardiac and pulmonary, explaining 60.7% of the total variance. In CFA, the original three-factor model showed poor fit and near-unity factor correlations (0.97–0.99). After six error covariances were added, the two-factor model showed borderline-to-acceptable fit (χ²/df = 2.00, CFI = 0.93, TLI = 0.91, RMSEA = 0.09 [90% CI 0.07–0.11], SRMR = 0.05) and fitted better than the one-factor model, but the two factors were very highly correlated ( r = 0.93). Cronbach’s alpha was 0.943 for the total scale, 0.925 for the cardiac subscale, and 0.868 for the pulmonary subscale. Total scores correlated with 6-minute walk distance (ρ = −0.37), oxygen saturation (ρ = −0.27), and functional class (ρ = 0.23) and were higher in patients reporting symptom exacerbation. The ICC for the total score was 0.991 (95% CI 0.979–0.996). The Turkish PAHSS showed acceptable content validity, high internal consistency, excellent test-retest reliability, and preliminary evidence of construct validity in outpatients with PH. Because the cardiac and pulmonary factors were highly correlated and EFA and CFA were performed in the same sample, the total score is recommended as the primary score. The scale may be useful for symptom assessment in PH outpatient follow-up, but further validation in larger, independent, and PAH-specific samples is needed. Not applicable.
No takes yet. Share an insight, caveat, or question.
Keşlikli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: